abs129.txt	objectives		to	analyze	self-reported	changes	in	physical	function	in	older	womenwith	breast	cancer	receiving	adjuvant	chemotherapy	design		secondary	analysis	of	the	cancer	and	leukemia	group	b	(calgb)	49907prospective	randomized	clinical	trial	setting		calgb	institutions	in	the	united	states	participants		women	aged	65	and	older	with	stage	i	to	iii	breast	cancer	enrolledin	calgb	49907	who	had	physical	function	data	from	before	and	after	receipt	ofadjuvant	chemotherapy	(n=256		mean	age	71	5		range	65-85)	measurements		participants	were	administered	the	physical	function	subscale	ofthe	european	organization	for	research	and	treatment	of	cancer	quality	of	lifequestionnaire	before	chemotherapy		at	the	end	of	chemotherapy		and	12	monthsafter	chemotherapy	initiation		functional	decline	was	defined	as	a	more	than10-point	decrease	from	baseline	at	each	time	point		resilience	was	defined	asreturn	to	within	10	points	of	baseline		multivariable	regression	was	used	toexamine	pretreatment	characteristics	associated	with	physical	function	changes	results		of	42%	of	participants	who	had	physical	function	decline	from	before	tothe	end	of	chemotherapy		47%	recovered	by	12	months	(were	resilient)		almostone-third	experienced	functional	decline	from	before	chemotherapy	to	12	monthslater		pretreatment	fatigue	was	a	risk	factor	for	functional	decline	from	beforeto	the	end	of	chemotherapy	(p=	02)		risk	factors	for	functional	decline	at	12months	included	pretreatment	dyspnea	(p=	007)	and	being	unmarried	(p=	01)	conclusion		functional	decline	was	common	in	older	women	receiving	adjuvantchemotherapy	for	breast	cancer	in	a	clinical	trial		although	half	recovered	theirphysical	function		one-third	had	a	clinically	meaningful	decline	at	12	months	strategies	are	needed	to	prevent	functional	decline	in	older	adults	receivingchemotherapy	
